<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00726869</url>
  </required_header>
  <id_info>
    <org_study_id>HuLuc63-1702</org_study_id>
    <nct_id>NCT00726869</nct_id>
  </id_info>
  <brief_title>A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies.</brief_title>
  <official_title>A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1/2, multi-center, open-label, multiple-dose, dose escalation study will evaluate&#xD;
      the combination of elotuzumab and bortezomib in subjects with MM following 1 to 3 prior&#xD;
      therapies. For the Phase 1 portion, elotuzumab will be administered by intravenous (IV)&#xD;
      infusion at up to 4 dose levels ranging from 2.5 mg/kg to 20.0 mg/kg within 30 minutes&#xD;
      following the administration of bortezomib at 1.3 mg/m^2 IV bolus. Bortezomib will be given&#xD;
      in 21 day cycles (twice weekly for 2 weeks on Days 1, 4, 8, and 11 followed by a 10-day rest&#xD;
      period). Elotuzumab will be administered as a separate infusion within 30 minutes following&#xD;
      bortezomib administration on the same days as the first and last dose of each bortezomib&#xD;
      cycle (i.e., Days 1 and 11).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The phase 2 portion of this study was not initiated because a decision was made to conduct a&#xD;
      phase 2 randomized clinical trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Enrollment has been halted&#xD;
  </why_stopped>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identify the maximum tolerated dose of elotuzumab in combination with bortezomib (phase 1).</measure>
    <time_frame>First cycle of treatment.</time_frame>
    <description>The highest dose level of elotuzumab at which &lt;= 1 dose-limiting toxicity occurs in 6 subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the efficacy of elotuzumab in combination with bortezomib (phase 2).</measure>
    <time_frame>Screening to the 30 day follow up visit.</time_frame>
    <description>Objective response rate (complete and partial response) according to European Group for Blood and Marrow Transplantation (EBMT) criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the efficacy of elotuzumab in combination with bortezomib (phase 1).</measure>
    <time_frame>Screening to the 30 day follow up visit.</time_frame>
    <description>Objective response rate according to EBMT criteria, duration of response, time to progression, and progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the safety of elotuzumab in combination with bortezomib (phase 1 and 2).</measure>
    <time_frame>Screening to the 30 day follow up visit.</time_frame>
    <description>Frequency, severity, and relationship of adverse events and serious adverse events with the combination of elotuzumab and bortezomib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the pharmacokinetic parameters of elotuzumab in combination with bortezomib (phase 1 and 2)</measure>
    <time_frame>Screening to the 30 day follow up visit.</time_frame>
    <description>Pharmacokinetic profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the immunogenicity of elotuzumab in combination with bortezomib (phase 1 and 2).</measure>
    <time_frame>Screening to the 30 day follow up visit.</time_frame>
    <description>Incidence of elotuzumab-specific antidrug antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the pharmacodynamics of elotuzumab in combination with bortezomib (phase 1 and 2).</measure>
    <time_frame>Screening to the 30 day follow up visit.</time_frame>
    <description>Changes in pharmacodynamic endpoints as they relate to dose, response, and toxicity of elotuzumab in combination with bortezomib</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.5 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5.0 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10.0 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20.0 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elotuzumab (HuLuc63)</intervention_name>
    <description>Cohort 1 - 2.5 mg/kg elotuzumab IV with bortezomib on Days 1 &amp; 11, with only Bortezomib IV on Days 4 &amp; 8; Cohort 2 - 5.0 mg/kg elotuzumab IV with bortezomib on Days 1 &amp; 11, with only Bortezomib IV on Days 4 &amp; 8; Cohort 3 - 10.0 mg/kg elotuzumab IV withbortezomib on Days 1 &amp; 11, with only Bortezomib IV on Days 4 &amp; 8; and Cohort 4 - 20.0 mg/kg elotuzumab IV with bortezomib on Days 1 &amp; 11, with only Bortezomib IV on Days 4 &amp; 8.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <other_name>Elotuzumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Males or females, age 18 years or older.&#xD;
&#xD;
          2. Diagnosis of MM and documentation of 1 to 3 prior therapies.&#xD;
&#xD;
          3. M-protein spike (complete immunoglobulin molecule) of &gt;= 1g/dL in serum and/or &gt;= 0.5&#xD;
             g excreted in a 24-hour urine collection sample. Light chain only disease is not an&#xD;
             inclusion criteria.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.&#xD;
&#xD;
          5. No prior bortezomib treatment OR responsive (PR or better) to prior bortezomib&#xD;
             treatment for a minimum of 3 months OR responsive to prior bortezomib treatment at the&#xD;
             time of going to another treatment or ceasing treatment.&#xD;
&#xD;
          6. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &lt;=3 x upper limit&#xD;
             of normal (ULN).&#xD;
&#xD;
          7. Total bilirubin &lt;=2 x ULN.&#xD;
&#xD;
          8. Serum creatinine &lt;=2.0 mg/dL (unless related to MM, then &lt;=3.0 mg/dL).&#xD;
&#xD;
          9. Must have adequate bone marrow function defined as:&#xD;
&#xD;
               -  Absolute neutrophil count &gt;1,000 cells/mm3 (1.0 x 10^9 cells/L) without growth&#xD;
                  factor support for 7 days;&#xD;
&#xD;
               -  Platelets &gt;=75,000 cells/mm3 (75 x 10^9 cells/L) without transfusion within 72&#xD;
                  hours of screening;&#xD;
&#xD;
               -  Hemoglobin &gt;=8 g/dL without red blood cell transfusion within 2 weeks of&#xD;
                  screening;&#xD;
&#xD;
         10. Serum calcium (corrected for albumin) level at or below ULN range (treatment of&#xD;
             hypercalcemia is allowed and subject may enroll if hypercalcemia returns to normal&#xD;
             with standard treatment); additional screening time may be allowed for confirmation -&#xD;
             consult with sponsor's medical monitor.&#xD;
&#xD;
         11. Use of appropriate contraception where applicable.&#xD;
&#xD;
         12. Negative urine pregnancy test where applicable.&#xD;
&#xD;
         13. Must have 2-dimensional echocardiogram indicating left ventricular ejection fraction&#xD;
             (LVEF) &gt;=45% within 30 days prior to the first dose of elotuzumab.&#xD;
&#xD;
         14. Ability to understand the purpose and risks of the study and provide signed and dated&#xD;
             informed consent and authorization to use protected health information (in accordance&#xD;
             with national and local subject privacy regulations).&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Life expectancy of less than 3 months.&#xD;
&#xD;
          2. Prior malignancy, except for adequately treated basal cell or squamous cell skin&#xD;
             cancer, in situ cervical cancer, or other cancer from which the subject has been&#xD;
             disease-free for at least 2 years.&#xD;
&#xD;
          3. Uncontrolled medical problems such as diabetes mellitus, coronary artery disease,&#xD;
             hypertension, unstable angina, arrhythmias, pulmonary,(including acute diffuse&#xD;
             infiltrative pulmonary and pericardial disease), hepatic, and renal diseases unless&#xD;
             renal insufficiency is felt to be secondary to MM.&#xD;
&#xD;
          4. Solitary bone or solitary extramedullary plasmacytoma as the only evidence of plasma&#xD;
             cell dyscrasia.&#xD;
&#xD;
          5. Prior treatment with bortezomib in 3 months prior to the first dose.&#xD;
&#xD;
          6. Thalidomide, lenalidomide cytotoxic chemotherapy, or corticosteroids (except prior to&#xD;
             infusion of first dose of study drug as prophylaxis for infusion reactions) within 2&#xD;
             weeks of the first dose of elotuzumab.&#xD;
&#xD;
          7. Prior therapy with anti-CD56+ therapeutics.&#xD;
&#xD;
          8. Radiotherapy within 2 weeks prior to the first dose of elotuzumab.&#xD;
&#xD;
          9. Investigational drug within 3 weeks or 3x the half-life of the investigational drug&#xD;
             (whichever is longer ) of the first dose of elotuzumab.&#xD;
&#xD;
         10. Prior peripheral stem cell transplant within 12 weeks of the first dose of elotuzumab.&#xD;
&#xD;
         11. Nitrogen mustard agents, melphalan, or monoclonal antibodies within 6 weeks of the&#xD;
             first dose of elotuzumab.&#xD;
&#xD;
         12. Neuropathy &gt;=Grade 2 (NCI CTCAE v3.0).&#xD;
&#xD;
         13. Current orthostatic hypotension.&#xD;
&#xD;
         14. Known active infections requiring antibiotic, antiviral, or antifungal therapy.&#xD;
&#xD;
         15. Serious psychiatric illness, active alcoholism, or drug addiction that may hinder or&#xD;
             confuse follow-up evaluation.&#xD;
&#xD;
         16. Any condition that in the investigator's opinion makes the subject unsuitable for&#xD;
             study participation.&#xD;
&#xD;
         17. Hypersensitivity to recombinant proteins or excipients in elotuzumab or bortezomib.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anil Singhal, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 63853</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 63855</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 63847</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 63852</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5936</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 63854</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 63850</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 63849</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 63848</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>July 29, 2008</study_first_submitted>
  <study_first_submitted_qc>July 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2008</study_first_posted>
  <last_update_submitted>August 22, 2012</last_update_submitted>
  <last_update_submitted_qc>August 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Patients After One to three Prior Therapies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Elotuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

